Obesity evidence dossier
Eloralintide
An amylin monotherapy advancing to Phase 3 with strong Phase 2 efficacy (up to 20.1% at 48 weeks) and being studied in combination with tirzepatide. Positions Lilly in the amylin class alongside CagriSema and petrelintide.
Total weight loss
17.5%
NCT06230523 · 9 mg weekly · week 48 · Includes treatment stops
Placebo-adjusted
15.2%
Difference from placebo in the same study when reported.
Study context
Amylin receptor agonist/Adults with obesity or overweight, without diabetes/263 participants across the study/48-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
NCT06230523 · 9 mg weekly · 48 weeks
Adults with obesity or overweight, without diabetes. 263 participants across the study (not this dose arm alone).
Includes treatment stops. Treatment-policy results estimate outcomes regardless of stopping treatment. Treatment-regimen estimand: includes outcomes regardless of treatment discontinuation.
- Average weight loss
- 17.5%
- Placebo group
- 2.3% loss
- Beyond placebo
- 15.2 percentage points (published difference)
- 95% confidence interval, beyond placebo
- 11.3–19.1 points
- Stopped due to adverse events
- Not verified for this result
Score: 70% × 72.0 total-loss points + 30% × 72.7 beyond-placebo points = 72/100, rounded. Conversion scales
Alternative analysis assuming continued treatment: 20.1% total loss. This is not the result used for the headline score. Alternative analysis source ↗
Billings et al., The Lancet, Figure 2D ↗Phase 2 · Journal article · Reviewed 2026-09-21
Evidence
Benchmark read
NCT06230523: Includes treatment stops. Treatment-regimen estimand: includes outcomes regardless of treatment discontinuation.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Gastrointestinal tolerability and fatigue are the main expected class watch items for amylin-based therapy.
Main cautions
Not approved; Phase 3 durability/discontinuation data are pending. Combination and diabetes cohorts should be read separately.
Upcoming catalyst
What to watch next
Phase 3 non-diabetic obesity readout (NCT07321886) and combination data.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT07392190
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company
Non-diabetic obesity
Mar 20, 2026
NCT06230523
Phase 2
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company
Non-diabetic obesity
Aug 28, 2025
NCT06916065
Phase 1
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
Eli Lilly and Company
Non-diabetic obesity
Jan 30, 2026
NCT06297616
Phase 1
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
Eli Lilly and Company
Non-diabetic obesity
Jan 16, 2026
NCT06916091
Phase 1
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
Eli Lilly and Company
Non-diabetic obesity
Nov 19, 2025
NCT06345066
Phase 1
A Study of LY3841136 in Overweight and Obese Participants
Eli Lilly and Company
Non-diabetic obesity
Oct 15, 2025
NCT07282600
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
Type 2 diabetes / obesity
Mar 20, 2026
NCT07321886
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly and Company
Type 2 diabetes / obesity
Mar 20, 2026
NCT06603571
Phase 2
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company
Type 2 diabetes / obesity
Sep 26, 2025
NCT07215559
Phase 2
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly and Company
Type 2 diabetes / obesity
Mar 2, 2026
NCT05295940
Phase 1
A Study of LY3841136 in Healthy and Overweight Participants
Eli Lilly and Company
Healthy volunteer
Apr 1, 2024